Cargando…

COVID‐19 after BNT162b2 two‐dose primary series does not improve the efficacy of a booster dose in nursing home residents

Detalles Bibliográficos
Autores principales:	Blain, Hubert, Tuaillon, Edouard, Gamon, Lucie, Pisoni, Amandine, Aouinti, Safa, Picot, Marie‐Christine, Bousquet, Jean
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Research Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10033849/ https://www.ncbi.nlm.nih.gov/pubmed/36973956 http://dx.doi.org/10.1002/clt2.12224

Ejemplares similares

Strong Decay of SARS-CoV-2 Spike Antibodies after 2 BNT162b2 Vaccine Doses and High Antibody Response to a Third Dose in Nursing Home Residents
por: Blain, Hubert, et al.
Publicado: (2022)

Antibody response after first and second BNT162b2 vaccination to predict the need for subsequent injections in nursing home residents
por: Tuaillon, Edouard, et al.
Publicado: (2022)

Amplitudes and kinetic of antibodies after second and third doses of BNT162b2 vaccine in nonagenarians and centenarians with and without prior SARS-CoV-2 infection
por: Tuaillon, Edouard, et al.
Publicado: (2022)

Corrigendum to: Analysing different exposures identifies that wearing masks and establishing COVID-19 areas reduce secondary-attack risk in aged-care facilities
por: Reyné, Bastien, et al.
Publicado: (2022)

Immune Responses After Vaccination With Primary 2-Dose ChAdOx1 Plus a Booster of BNT162b2 or Vaccination With Primary 2-Dose BNT162b2 Plus a Booster of BNT162b2 and the Occurrence of Omicron Breakthrough Infection
por: Choi, Seong-Ho, et al.
Publicado: (2023)

Comparison of Waning Immunity Between Booster Vaccination and 2-Dose Vaccination With BNT162b2
por: Jung, Jiwon, et al.
Publicado: (2022)

Mucosal immune response after the booster dose of the BNT162b2 COVID-19 vaccine
por: Azzi, Lorenzo, et al.
Publicado: (2023)

Correlates of protection for booster doses of the SARS-CoV-2 vaccine BNT162b2
por: Hertz, Tomer, et al.
Publicado: (2023)

Efficacy of a Test-Retest Strategy in Residents and Health Care Personnel of a Nursing Home Facing a COVID-19 Outbreak
por: Blain, Hubert, et al.
Publicado: (2020)

Protective antibodies and T cell responses to Omicron variant after the booster dose of BNT162b2 vaccine
por: Naaber, Paul, et al.
Publicado: (2022)

2373. "Longitudinal Investigation of Avidity Maturation following Multiple Doses of BNT162b2 mRNA Vaccine Including Bivalent Boosters among Nursing Home Residents and Healthcare Workers"
por: Oyebanji, Oladayo A, et al.
Publicado: (2023)

Protection following BNT162b2 booster in adolescents substantially exceeds that of a fresh 2-dose vaccine
por: Amir, Ofra, et al.
Publicado: (2022)

Booster dose of BNT162b2 after two doses of CoronaVac improves neutralization of SARS-CoV-2 Omicron variant
por: Campos, Guilherme R. F., et al.
Publicado: (2022)

Antibody response after a booster dose of BNT162B2mRNA and inactivated COVID-19 vaccine
por: Yigit, Metin, et al.
Publicado: (2022)

Self-Reported and Physiologic Reactions to Third BNT162b2 mRNA COVID-19 (Booster) Vaccine Dose
por: Mofaz, Merav, et al.
Publicado: (2022)

Anti‐spike IgG antibody kinetics following the second and third doses of BNT162b2 vaccine in nursing home residents
por: Jeulin, Helene, et al.
Publicado: (2022)

Pronounced antibody elevation after SARS‐CoV‐2 BNT162b2 mRNA booster vaccination in nursing home residents
por: Chong, Yong, et al.
Publicado: (2022)

A Case of Idiopathic Thrombocytopenic Purpura After Booster Dose of BNT162b2 (Pfizer-Biontech) COVID-19 Vaccine
por: Malayala, Srikrishna V, et al.
Publicado: (2021)

Dynamics of SARS-CoV-2 Antibody Response to CoronaVac followed by Booster Dose of BNT162b2 Vaccine
por: Fonseca, Marcela Helena Gambim, et al.
Publicado: (2022)

A Randomized Clinical Trial of a Fractional Low Dose of BNT162b2 Booster in Adults Following AZD1222
por: Nantanee, Rapisa, et al.
Publicado: (2022)

Serological response to a third booster dose of BNT162b2 COVID‐19 vaccine among seronegative cancer patients
por: Shmueli, Einat Shacham, et al.
Publicado: (2022)

Cerebellar and brainstem stroke possibly associated with booster dose of BNT162b2 (Pfizer-BioNTech) COVID-19 vaccine
por: Thomas, Michael George, et al.
Publicado: (2023)

Immunogenicity of a Fractional Dose of mRNA BNT162b2 COVID-19 Vaccine for Primary Series and Booster Vaccination among Healthy Adolescents
por: Puthanakit, Thanyawee, et al.
Publicado: (2022)

Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial
por: Munro, Alasdair P S, et al.
Publicado: (2022)

Effectiveness of Booster Dose of Anti SARS-CoV-2 BNT162b2 in Cirrhosis: Longitudinal Evaluation of Humoral and Cellular Response
por: Giambra, Vincenzo, et al.
Publicado: (2022)

Evaluation of the Effectiveness of BNT162b2 Primary Vaccination and Booster Dose to SARS-CoV-2 in Eliciting Stable Mucosal Immunity
por: Lambiase, Alessandro, et al.
Publicado: (2022)

Comparison of SARS-CoV-2 Antibody Levels after a Third Heterologous and Homologous BNT162b2 Booster Dose
por: Gareayaghi, Nesrin, et al.
Publicado: (2022)

Immunogenicity and SARS-CoV-2 Infection following the Fourth BNT162b2 Booster Dose among Health Care Workers
por: Shachor-Meyouhas, Yael, et al.
Publicado: (2023)

Could Prior COVID-19 Affect the Neutralizing Antibody after the Third BNT162b2 Booster Dose: A Longitudinal Study
por: Erdem, Mustafa Genco, et al.
Publicado: (2023)

BNT162b2 Vaccine Booster and Mortality Due to Covid-19
por: Arbel, Ronen, et al.
Publicado: (2021)

Frosted branch angiitis after booster vaccination with BNT162b2
por: Haas, A.-M., et al.
Publicado: (2023)

CoronaVac or BNT162b2 Vaccine as a Third Dose
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2022)

Neutralising antibody responses to SARS-CoV-2 omicron among elderly nursing home residents following a booster dose of BNT162b2 vaccine: A community-based, prospective, longitudinal cohort study
por: Bruel, Timothée, et al.
Publicado: (2022)

Third BNT162b2 Vaccine Booster Dose against SARS-CoV-2-Induced Antibody Response among Healthcare Workers
por: Hussein, Khetam, et al.
Publicado: (2022)

Effect of vaccine dosing intervals on Omicron surrogate neutralization after three doses of BNT162b2
por: Prusinkiewicz, Martin A., et al.
Publicado: (2023)

Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel
por: Bar-On, Yinon M., et al.
Publicado: (2021)

Immunogenicity of a BNT162b2 vaccine booster in health-care workers
por: Saiag, Esther, et al.
Publicado: (2021)

Immunogenicity evaluation after BNT162b2 booster vaccination in healthcare workers
por: Zurac, Sabina, et al.
Publicado: (2022)

Effectiveness of the BNT162b2 and the CoronaVac vaccines and boosters in healthcare workers
por: Çulpan, Hazal Cansu, et al.
Publicado: (2023)

Delayed second dose of the BNT162b2 vaccine: innovation or misguided conjecture?
por: Robertson, John F R, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_bknj27vclbqjiugt30cjec4vn6